GSK PLC-SPON ADR (GSK) Fundamental Analysis & Valuation

NYSE:GSK • US37733W2044

Current stock price

52.22 USD
+0.16 (+0.31%)
Last:

This GSK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. GSK Profitability Analysis

1.1 Basic Checks

  • GSK had positive earnings in the past year.
  • GSK had a positive operating cash flow in the past year.
  • Each year in the past 5 years GSK has been profitable.
  • GSK had a positive operating cash flow in each of the past 5 years.
GSK Yearly Net Income VS EBIT VS OCF VS FCFGSK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.35%, GSK belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
  • With an excellent Return On Equity value of 34.90%, GSK belongs to the best of the industry, outperforming 95.83% of the companies in the same industry.
  • GSK's Return On Invested Capital of 19.19% is amongst the best of the industry. GSK outperforms 95.31% of its industry peers.
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROIC 19.19%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GSK Yearly ROA, ROE, ROICGSK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K -2K

1.3 Margins

  • With an excellent Profit Margin value of 17.50%, GSK belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
  • GSK's Profit Margin has declined in the last couple of years.
  • GSK has a Operating Margin of 27.47%. This is amongst the best in the industry. GSK outperforms 93.23% of its industry peers.
  • GSK's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 72.67%, GSK belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
  • In the last couple of years the Gross Margin of GSK has remained more or less at the same level.
Industry RankSector Rank
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
GSK Yearly Profit, Operating, Gross MarginsGSK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. GSK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GSK is creating value.
  • GSK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GSK Yearly Shares OutstandingGSK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
GSK Yearly Total Debt VS Total AssetsGSK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

  • An Altman-Z score of 2.26 indicates that GSK is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.26, GSK is doing good in the industry, outperforming 65.10% of the companies in the same industry.
  • GSK has a debt to FCF ratio of 3.73. This is a good value and a sign of high solvency as GSK would need 3.73 years to pay back of all of its debts.
  • GSK has a better Debt to FCF ratio (3.73) than 88.54% of its industry peers.
  • GSK has a Debt/Equity ratio of 0.90. This is a neutral value indicating GSK is somewhat dependend on debt financing.
  • GSK has a worse Debt to Equity ratio (0.90) than 70.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Altman-Z 2.26
ROIC/WACC2
WACC9.61%
GSK Yearly LT Debt VS Equity VS FCFGSK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 0.82 indicates that GSK may have some problems paying its short term obligations.
  • GSK has a worse Current ratio (0.82) than 86.46% of its industry peers.
  • A Quick Ratio of 0.54 indicates that GSK may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.54, GSK is not doing good in the industry: 86.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.54
GSK Yearly Current Assets VS Current LiabilitesGSK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GSK Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.84% over the past year.
  • Measured over the past 5 years, GSK shows a small growth in Earnings Per Share. The EPS has been growing by 3.55% on average per year.
  • The Revenue has been growing slightly by 4.11% in the past year.
  • GSK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%

3.2 Future

  • Based on estimates for the next years, GSK will show a small growth in Earnings Per Share. The EPS will grow by 5.01% on average per year.
  • Based on estimates for the next years, GSK will show a small growth in Revenue. The Revenue will grow by 2.87% on average per year.
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GSK Yearly Revenue VS EstimatesGSK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
GSK Yearly EPS VS EstimatesGSK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. GSK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.21, which indicates a very decent valuation of GSK.
  • Compared to the rest of the industry, the Price/Earnings ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 88.54% of the companies listed in the same industry.
  • GSK is valuated cheaply when we compare the Price/Earnings ratio to 25.79, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 10.31, which indicates a very decent valuation of GSK.
  • 88.02% of the companies in the same industry are more expensive than GSK, based on the Price/Forward Earnings ratio.
  • GSK is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.21
Fwd PE 10.31
GSK Price Earnings VS Forward Price EarningsGSK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GSK indicates a rather cheap valuation: GSK is cheaper than 92.71% of the companies listed in the same industry.
  • 86.46% of the companies in the same industry are more expensive than GSK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 16.55
EV/EBITDA 7.28
GSK Per share dataGSK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • GSK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of GSK may justify a higher PE ratio.
PEG (NY)1.29
PEG (5Y)3.16
EPS Next 2Y8.39%
EPS Next 3Y6.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. GSK Dividend Analysis

5.1 Amount

  • GSK has a Yearly Dividend Yield of 3.45%. Purely for dividend investing, there may be better candidates out there.
  • GSK's Dividend Yield is rather good when compared to the industry average which is at 0.77. GSK pays more dividend than 94.79% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.91, GSK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.45%

5.2 History

  • The dividend of GSK decreases each year by -9.84%.
  • GSK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • The dividend of GSK decreased recently.
Dividend Growth(5Y)-9.84%
Div Incr Years1
Div Non Decr Years1
GSK Yearly Dividends per shareGSK Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 44.86% of the earnings are spent on dividend by GSK. This is a bit on the high side, but may be sustainable.
DP44.86%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
GSK Yearly Income VS Free CF VS DividendGSK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B
GSK Dividend Payout.GSK Dividend Payout, showing the Payout Ratio.GSK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

GSK Fundamentals: All Metrics, Ratios and Statistics

GSK PLC-SPON ADR

NYSE:GSK (3/19/2026, 11:19:47 AM)

52.22

+0.16 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)04-29
Inst Owners41.42%
Inst Owner Change181.39%
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap104.79B
Revenue(TTM)32.67B
Net Income(TTM)5.72B
Analysts68.75
Price Target54.76 (4.86%)
Short Float %0.55%
Short Ratio1.88
Dividend
Industry RankSector Rank
Dividend Yield 3.45%
Yearly Dividend1.61
Dividend Growth(5Y)-9.84%
DP44.86%
Div Incr Years1
Div Non Decr Years1
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.74%
Min EPS beat(2)8.69%
Max EPS beat(2)12.8%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)7.67%
Max EPS beat(4)12.8%
EPS beat(8)8
Avg EPS beat(8)11.8%
EPS beat(12)11
Avg EPS beat(12)9.51%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.76%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-1.6%
Max Revenue beat(4)-0.04%
Revenue beat(8)3
Avg Revenue beat(8)-0.16%
Revenue beat(12)7
Avg Revenue beat(12)1.25%
Revenue beat(16)9
Avg Revenue beat(16)-0.18%
PT rev (1m)6.09%
PT rev (3m)12.87%
EPS NQ rev (1m)-0.56%
EPS NQ rev (3m)-5.81%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-1.31%
Revenue NY rev (1m)-0.84%
Revenue NY rev (3m)-0.73%
Valuation
Industry RankSector Rank
PE 11.21
Fwd PE 10.31
P/S 2.41
P/FCF 16.55
P/OCF 10.17
P/B 4.81
P/tB N/A
EV/EBITDA 7.28
EPS(TTM)4.66
EY8.92%
EPS(NY)5.06
Fwd EY9.7%
FCF(TTM)3.15
FCFY6.04%
OCF(TTM)5.14
OCFY9.83%
SpS21.67
BVpS10.86
TBVpS-4.9
PEG (NY)1.29
PEG (5Y)3.16
Graham Number33.75
Profitability
Industry RankSector Rank
ROA 9.35%
ROE 34.9%
ROCE 22.59%
ROIC 19.19%
ROICexc 20.98%
ROICexgc 60.71%
OM 27.47%
PM (TTM) 17.5%
GM 72.67%
FCFM 14.56%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-1.36%
OM growth 5Y2.22%
PM growth 3Y-29.99%
PM growth 5Y-5.81%
GM growth 3Y0.72%
GM growth 5Y0.77%
F-Score9
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF 3.73
Debt/EBITDA 1.15
Cap/Depr 79.01%
Cap/Sales 9.14%
Interest Coverage 13.22
Cash Conversion 60.7%
Profit Quality 83.21%
Current Ratio 0.82
Quick Ratio 0.54
Altman-Z 2.26
F-Score9
WACC9.61%
ROIC/WACC2
Cap/Depr(3y)99.36%
Cap/Depr(5y)105.31%
Cap/Sales(3y)8.79%
Cap/Sales(5y)9.19%
Profit Quality(3y)103.9%
Profit Quality(5y)92.12%
High Growth Momentum
Growth
EPS 1Y (TTM)7.84%
EPS 3Y5.13%
EPS 5Y3.55%
EPS Q2Q%9.91%
EPS Next Y8.66%
EPS Next 2Y8.39%
EPS Next 3Y6.8%
EPS Next 5Y5.01%
Revenue 1Y (TTM)4.11%
Revenue growth 3Y3.66%
Revenue growth 5Y6.05%
Sales Q2Q%6.17%
Revenue Next Year4.21%
Revenue Next 2Y4.48%
Revenue Next 3Y3.95%
Revenue Next 5Y2.87%
EBIT growth 1Y15.03%
EBIT growth 3Y2.25%
EBIT growth 5Y8.41%
EBIT Next Year28.71%
EBIT Next 3Y11.62%
EBIT Next 5Y8.05%
FCF growth 1Y33.15%
FCF growth 3Y-2.59%
FCF growth 5Y-5.17%
OCF growth 1Y18.11%
OCF growth 3Y1.5%
OCF growth 5Y-1.72%

GSK PLC-SPON ADR / GSK Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GSK PLC-SPON ADR?

ChartMill assigns a fundamental rating of 6 / 10 to GSK.


What is the valuation status of GSK PLC-SPON ADR (GSK) stock?

ChartMill assigns a valuation rating of 8 / 10 to GSK PLC-SPON ADR (GSK). This can be considered as Undervalued.


How profitable is GSK PLC-SPON ADR (GSK) stock?

GSK PLC-SPON ADR (GSK) has a profitability rating of 8 / 10.


What is the financial health of GSK PLC-SPON ADR (GSK) stock?

The financial health rating of GSK PLC-SPON ADR (GSK) is 4 / 10.


What is the earnings growth outlook for GSK PLC-SPON ADR?

The Earnings per Share (EPS) of GSK PLC-SPON ADR (GSK) is expected to grow by 8.66% in the next year.